SK281110B6 - Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl)alkyl]- -pyran-2-ónu - Google Patents

Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl)alkyl]- -pyran-2-ónu Download PDF

Info

Publication number
SK281110B6
SK281110B6 SK1339-99A SK133999A SK281110B6 SK 281110 B6 SK281110 B6 SK 281110B6 SK 133999 A SK133999 A SK 133999A SK 281110 B6 SK281110 B6 SK 281110B6
Authority
SK
Slovakia
Prior art keywords
formula
compound
acid
solution
dihydroxy
Prior art date
Application number
SK1339-99A
Other languages
English (en)
Slovak (sk)
Inventor
Donald Eugene Butler
Tung Van Le
Thomas Norman Nanninga
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of SK281110B6 publication Critical patent/SK281110B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
SK1339-99A 1993-03-03 1994-02-24 Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl)alkyl]- -pyran-2-ónu SK281110B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/025,701 US5298627A (en) 1993-03-03 1993-03-03 Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
PCT/US1994/002180 WO1994020492A1 (en) 1993-03-03 1994-02-24 Novel process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis

Publications (1)

Publication Number Publication Date
SK281110B6 true SK281110B6 (sk) 2000-12-11

Family

ID=21827596

Family Applications (4)

Application Number Title Priority Date Filing Date
SK1339-99A SK281110B6 (sk) 1993-03-03 1994-02-24 Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl)alkyl]- -pyran-2-ónu
SK1341-99A SK281984B6 (sk) 1993-03-03 1994-02-24 Pyrolkarboxamidy
SK1090-95A SK281109B6 (sk) 1993-03-03 1994-02-24 Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl) alkyl] pyran-2-ónov a medziprodukty na ich výrobu
SK1340-99A SK281983B6 (sk) 1993-03-03 1994-02-24 Pyrolkarboxamidy

Family Applications After (3)

Application Number Title Priority Date Filing Date
SK1341-99A SK281984B6 (sk) 1993-03-03 1994-02-24 Pyrolkarboxamidy
SK1090-95A SK281109B6 (sk) 1993-03-03 1994-02-24 Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl) alkyl] pyran-2-ónov a medziprodukty na ich výrobu
SK1340-99A SK281983B6 (sk) 1993-03-03 1994-02-24 Pyrolkarboxamidy

Country Status (19)

Country Link
US (8) US5298627A (cs)
EP (1) EP0687263B1 (cs)
JP (1) JP3510253B2 (cs)
KR (1) KR100302431B1 (cs)
AT (1) ATE156127T1 (cs)
AU (1) AU677047B2 (cs)
CA (1) CA2155952C (cs)
CZ (4) CZ284365B6 (cs)
DE (1) DE69404632T2 (cs)
DK (1) DK0687263T3 (cs)
ES (1) ES2108435T3 (cs)
FI (3) FI109999B (cs)
GR (1) GR3024784T3 (cs)
HU (1) HU222177B1 (cs)
NO (3) NO308529B1 (cs)
NZ (1) NZ262830A (cs)
RU (1) RU2138497C1 (cs)
SK (4) SK281110B6 (cs)
WO (1) WO1994020492A1 (cs)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4415331A1 (de) * 1994-05-02 1995-11-09 Sobrevin Fadenspeichervorrichtung mit einstellbarem Fadenabzugswiderstand
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
BR9813760A (pt) * 1997-12-19 2000-10-03 Warner Lambert Export Limited Processo para a sìntese de 1,3-dióis
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
IN191236B (cs) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
ATE320415T1 (de) * 1999-12-17 2006-04-15 Pfizer Science & Tech Ltd Verfahren zur herstellung von kristallin atorvastin kalcium
AU776613B2 (en) 1999-12-17 2004-09-16 Pfizer Science And Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7521216B2 (en) * 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6528661B2 (en) * 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
NZ527048A (en) * 2000-12-27 2004-12-24 Ciba Sc Holding Ag Crystalline forms of atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1728785A1 (en) * 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
NZ529557A (en) * 2001-06-29 2005-05-27 Warner Lambert Co Crystalline forms of `R-(R*,R*)!-2-(4-fluorophenyl)- beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- 'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
EP1406860A1 (en) * 2001-07-06 2004-04-14 Teva Pharmaceutical Industries Limited Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
DE60235365D1 (de) * 2001-07-06 2010-04-01 Basf Se Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
RU2304139C2 (ru) 2001-07-30 2007-08-10 Д-р Редди'с Лабораторис Лтд Кристаллические формы vi и vii кальциевой соли аторвастатина
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1)
CA2412012C (en) * 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
JP4422488B2 (ja) * 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
CA2480325A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
AU2003251523A1 (en) * 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
US20060211761A1 (en) * 2002-07-08 2006-09-21 Yatendra Kumar Hmg-coa-reductase inhibitors
EP1534704B1 (en) * 2002-08-06 2007-08-01 Warner-Lambert Company LLC Process for preparing 5-(4-fluorophenyl)-1-¬2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl|-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
ES2310676T3 (es) 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007516227A (ja) * 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
KR101113163B1 (ko) * 2003-07-25 2012-02-17 브래드포드 파마 리미티드 스타틴, 특히 아토르바스타틴의 제조에 유용한 중간체화합물 및 그 제조방법
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
MXPA06003003A (es) * 2003-09-17 2006-06-23 Warner Lambert Co Formas cristalinas de acido [r-(r*, r*)]-2-(4- fluorofenil)-(, (-dihidroxi -5-(1- metiletil)-3 -fenil-4 -[(fenilamino) -carbonil]- 1h-pirrol -1-heptanoico.
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1691803A1 (en) * 2003-12-05 2006-08-23 Warner-Lambert Company LLC N-alkyl pyrroles as hmg-coa reductase inhibitors
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
NO330092B1 (no) 2004-03-17 2011-02-14 Ranbaxy Lab Ltd Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form
MXPA06011987A (es) * 2004-04-16 2007-01-16 Pfizer Prod Inc Procedimiento para formar calcio de atorvastatina amorfa.
BRPI0510713A (pt) * 2004-05-05 2007-11-20 Pfizer Prod Inc formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
EP1771412A2 (en) * 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
WO2006021969A1 (en) 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
NZ554541A (en) * 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US7511152B2 (en) 2004-12-09 2009-03-31 Merck & Co., Inc. Estrogen receptor modulators
CA2498978A1 (en) * 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
ES2510494T3 (es) 2005-03-02 2014-10-21 Merck Sharp & Dohme Corp. Composición para la inhibición de la catepsina K
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
RU2409563C2 (ru) * 2005-04-08 2011-01-20 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007029216A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
CA2621507A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) * 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
KR20080007561A (ko) * 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2007231018A (ja) * 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd アトルバスタチンヘミカルシウムの結晶形の調製方法
AU2007237904B2 (en) 2006-04-19 2011-03-03 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
WO2008106662A2 (en) 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
KR20100017866A (ko) 2007-05-21 2010-02-16 노파르티스 아게 Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
DE102011119719A1 (de) 2011-11-30 2013-06-06 GEA CFS Bühl GmbH Verfahren zum Aufschneiden eines Lebensmittelriegels unter Verwendung eines Schwingungssensors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
KR20160065854A (ko) 2013-10-08 2016-06-09 머크 샤프 앤드 돔 코포레이션 카텝신 시스테인 프로테아제 억제제
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN105085497B (zh) * 2015-06-26 2017-12-26 上海应用技术学院 多取代吡咯类他汀含氟衍生物及其用途
MA43190A (fr) 2015-11-06 2018-09-12 Gemphire Therapeutics Inc Traitement de la dyslipidémie mixte
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
CN108558726A (zh) * 2018-03-14 2018-09-21 湖北广济药业股份有限公司 一种高纯度阿托伐他汀钙的制备方法
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP2022529341A (ja) 2019-04-19 2022-06-21 リガンド・ファーマシューティカルズ・インコーポレイテッド 化合物の結晶形、および化合物の結晶形を生成する方法
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
CN115087638B (zh) 2019-12-17 2023-11-24 默沙东公司 Prmt5抑制剂
CN111362856B (zh) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 一种利用微反应装置生产阿托伐他汀钙的方法
CN116102482A (zh) * 2022-08-17 2023-05-12 重庆普佑生物医药有限公司 一种阿托伐他汀钙的制备方法
CN120917311A (zh) 2023-03-02 2025-11-07 卡西蒙生物技术有限责任公司 用于诊断癌症和/或急性炎性疾病的手段和方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3702283A1 (de) * 1987-01-27 1988-08-04 Bayer Ag Verfahren zur herstellung von 2-cyano-2-oximino-acetamid-derivaten
JPH0774194B2 (ja) * 1987-06-11 1995-08-09 財団法人微生物化学研究会 生理活性を有する新規なアクチノニン誘導体
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
CA2155952C (en) 2005-06-14
HU9502575D0 (en) 1995-11-28
FI20021438L (fi) 2002-08-02
JPH08507521A (ja) 1996-08-13
SK281984B6 (sk) 2001-09-11
US5489691A (en) 1996-02-06
FI109999B (fi) 2002-11-15
US5489690A (en) 1996-02-06
ES2108435T3 (es) 1997-12-16
AU677047B2 (en) 1997-04-10
ATE156127T1 (de) 1997-08-15
KR960701043A (ko) 1996-02-24
CA2155952A1 (en) 1994-09-15
HUT75034A (en) 1997-03-28
CZ220695A3 (en) 1995-12-13
NO994708D0 (no) 1999-09-27
KR100302431B1 (ko) 2001-11-22
AU6274294A (en) 1994-09-26
US5397792A (en) 1995-03-14
US5446054A (en) 1995-08-29
SK281983B6 (sk) 2001-09-11
FI954073A0 (fi) 1995-08-30
WO1994020492A1 (en) 1994-09-15
NO308529B1 (no) 2000-09-25
RU2138497C1 (ru) 1999-09-27
DE69404632T2 (de) 1998-01-29
CZ285555B6 (cs) 1999-09-15
NO994708L (no) 1999-11-22
HU222177B1 (hu) 2003-04-28
CZ47998A3 (cs) 1999-08-11
US5342952A (en) 1994-08-30
CZ284365B6 (cs) 1998-11-11
CZ285447B6 (cs) 1999-08-11
FI20021437L (fi) 2002-08-02
DE69404632D1 (de) 1997-09-04
JP3510253B2 (ja) 2004-03-22
FI954073L (fi) 1995-08-30
DK0687263T3 (da) 1998-02-16
GR3024784T3 (en) 1998-01-30
NO308898B1 (no) 2000-11-13
SK109095A3 (en) 1995-12-06
EP0687263B1 (en) 1997-07-30
FI20021438A7 (fi) 2002-08-02
NO20000910L (no) 2000-03-13
EP0687263A1 (en) 1995-12-20
NO953438D0 (no) 1995-09-01
NO953438L (no) 1995-11-01
US5298627A (en) 1994-03-29
CZ285554B6 (cs) 1999-09-15
FI20021437A7 (fi) 2002-08-02
US5470981A (en) 1995-11-28
NZ262830A (en) 1996-11-26
NO20000910D0 (no) 2000-02-24
NO313799B1 (no) 2002-12-02
SK281109B6 (sk) 2000-12-11
US5510488A (en) 1996-04-23

Similar Documents

Publication Publication Date Title
SK281110B6 (sk) Spôsob výroby trans-6-[2-(substituovaný pyrol-1-yl)alkyl]- -pyran-2-ónu
EP1351963B1 (en) A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
JP3429500B2 (ja) ４−シアノ−３−ヒドロキシ酪酸エステルの製造方法
SK280938B6 (sk) Spôsob syntézy (4r-cis)-1,1-dimetyletyl-6-kyanometyl-2,2- -dimetyl-1,3-dioxán-4-acetátu a medziprodukty tohto spôsobu
JP5023068B2 (ja) （３ｒ，５ｒ）―７―［２―（４―フルオロフェニル）―５―イソプロピル―３―フェニル―４―［（４―ヒドロキシメチルフェニルアミノ）カルボニル］―ピロール―１―イル］―３，５―ジヒドロキシ―ヘプタン酸ヘミカルシウム塩の製法
CA2498978A1 (en) An improved process for the preparation of atorvastatin and intermediates
US7615647B2 (en) Process for producing atorvastatin hemicalcium
NO177423B (no) Forbedret fremgangsmåte for fremstilling av trans-6-[2-(substituert-pyrrol-yl)alkylÅpyran-2-on-inhibitorer for kolesterolsyntese